ACNP Task Force Ties to Pharma

Joseph John Mann, M.D. — Task Force Co-Chair

The Paul Janssen Professor of Translational Neuroscience in Psychiatry and Radiology, Columbia University College of Physicians and Surgeons; Chief, Department of Neuroscience, New York State Psychiatric Institute; ACNP

Industry Affiliations:
•    Consultant and expert wtiness: GlaxoSmithKline, Pfizer, 2000, 2001 (lamotrigine; Zoloft)
•    Grants/Research Support: PET ligand development grant from Pfizer (2003), Beta-amyloid imaging grant from GlaxoSmithKline (2005)
•    Participated in GlaxoSmithKline Advisory group meeting on lamotrigine (2002);
•    Received three years of funding from Janssen Pharmaceutica for research involving all suicide victims in a region of Hungary  (http://www.hu.afsp.org/english/fr_hun_eng.htm); accessed 01/19/03);
•    Received funding from Eli Lilly for a study on the safety and biological mechanisms of action of norepinephrine and serotonin reuptake inhibitor antidepressants (1990).  (http://www.healyprozac.com/Trials/Tobin/Transcripts/5-31%20Suhaney-Mann.txt,  p.1622; accessed 01/19/04)   http://www.cspinet.org/cgi-bin/integrity.cgi

Graham Emslie, MD– Task Force Co-Chair

Chief, Division of Child and Adolescent Psychiatry and Professor of Psychiatry,
The University of Texas Southwestern Medical Center at Dallas; ACNP
Industry Affiliations:
•    Consultant/Speaker’s Bureau: Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, McNeil, Otsuka, Pfizer, Inc. Wyeth-Ayerst
•    Grants/Research Support: Eli Lilly, Novartis, Organon
•    Serves on the Corporate Contributions and Research Committee for the American Academy of Child and Adolescent Psychiatry.
•    Leading participant in a consensus panel for child and adolescent bipolar disorder funded by:  Abbott, Brystol-Myers Squibb, GlaxoSmithKline, INC Research, Janssen, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, and Solvay. Participants did not disclose compensation or affiliations. http://www.liebertpub.com/cap/jcappaper1.pdf
•    Served on Texas Children’s Medication  “Expert Consensus Panel”
•    Principle investigator fluoxetine (Prozac) pediatric trials resulting in FDA approval for use in children; Co-Author of dubious Paroxetine (Paxil) Study 329 Report: “Effacy of paroxetine in the treatment of adolescent major depression” (JAMA 2003; 290:1033-41). The report failed to disclose it was based on selected data. See sponsor (GSK) memo at: http://www.ahrp.org/risks/SSRI0204/GSKpaxil/index.php   (http://www3.utsouthwestern.edu/psychiatry/facbios/emslie.htm; http://www.cspinet.org/cgi-bin/integrity.cgi

Ross J Baldessarini, MD

Professor of Psychiatry and Neuroscience, Harvard Medical School
Director, Laboratories for Psychiatric Research, Mailman Research Center
Director, Bipolar & Psychiatric Disorders/Director, Psychopharmacology, McLean Hospital; ACNP
Industry Affiliations:
•    Consultant/Research Collaborator: Auritec Laboratories, Eli Lilly Laboratories, IFI SpA, Janssen Pharmaceuticals, JDS Corporation, NeuroHealing Pharmaceuticals, also Auritec, Biostream, Protarga, and Vertex, Protarga and Solvay. http://www.medscape.com/viewprogram/353_authors
•    Grants/Research Support: Eli Lilly Laboratories (former grant recipient), Janssen, also Biostream See:http://www.psychiatrist.com/achi/6409.pdf

William Beardslee, MD

Psychiatrist-in-Chief and Chair, Children’s Hospital Department of Psychiatry; Professor of Child Psychiatry, Harvard Medical School  No Industry Affiliations

Jan Fawcett, MD

Professor of Psychiatry, University of New Mexico; ACNP
Industry Affiliations:
•    Consultant: Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories, Janssen Pharmaceutica, GlaxoSmithKline, Merck & Co. Inc., Pfizer, Inc., Pharmacia & Upjohn, Wyeth-Ayerst Laboratories
•    Speaker’s Bureau: Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer/Roerig, Pharmacia, GlaxoSmithKline, Solvay Pharmaceuticals, Inc., Wyeth-Ayerst Laboratories
•    Grants/Research Support: National Institute of Mental Health, Abbott Laboratories, Astra Zeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly and Company, Organon, Pfizer, Inc., Wyeth-Ayerst Laboratories  http://www.cspinet.org/cgi-bin/integrity.cgi

Fred Goodwin, MD

Research Professor of Psychiatry and Director, Psychopharmacology Research Center, George Washington University; Former Director of the National Institute of Mental Health; ACNP
Industry Affiliations:
•    Consultant: Glaxo, Lilly, Pfizer, Bristol Myers Squibb, Solvay. Elan, Novartis
•    Speakers Bureau: Bristol Myers Squibb, Solvay, Glaxo, Pfizer, Janssen, Lilly, AstraZeneca, Grants/Research Support: Abbott Laboratories, Glaxo, Solvay, Janssen, Pfizer, Lilly, Forest, Sanofi.
•    Participated in a consensus panel for child and adolescent bipolar disorder funded by: Abbott, Brystol-Myers Squibb, GlaxoSmithKline, INC Research, Janssen, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, and Solvay.
Participants did not disclose compensation or affiliations. http://www.liebertpub.com/cap/jcappaper1.pdf

Andrew C Leon, PhD

Professor of Biostatistics in Psychiatry and Professor of Public Health,
Weill Medical College of Cornell University.
Industry Affiliations:
•    Consultant: Cyberonics, Inc., Cortex Pharmaceuticals, Pfizer.
•    Wrote a manuscript and presentation for Forest Laboratories titled, "Are Two Antidepressant Mechanisms Better than One? Issues in Clinical Trial Design and Analysis."   On file with CSPI)  http://www.cspinet.org/cgi-bin/integrity.cgi

Herb Meltzer, MD

Professor of Psychiatry & Pharmacology, Director Division of Psychopharmacology
President, Collegium Internationale Neuropsychopharmacologicum (CINP),
Vanderbilt University Medical Center; ACNP
Industry Affiliations:
•    Consultant, Speaker’s Bureau, Honorarium,
•    Grant/Research Support: Eli Lilly, Pfizer, GlaxoSmithKline, Janssen, AstraZeneca

Neal Ryan, MD

Professor of Psychiatry, Western Psychiatric Institute & Clinic, University of Pittsburgh; ACNP
Industry Affiliations:
•    Consultant: GlaxoSmithKline (designed study and a performance site for the GSK study of paroxetine in adolescents and was second author on the resulting publication* as well as a co-author on related letters to the editor including one letter related to suicidality assessment in that study)
•    Consultant: GlaxoSmithKline (examination of their data related to suicidality in their aggregate paroxetine data.)
•    Consultant (design of studies of antidepressants in youth): Pfizer, GSK, and Wyeth
•    Primary Investigator: Wyeth (Pittsburgh performance site for the study of Venlafaxine (Effexor) and children.)
•    Served on Texas Children’s Medication  “Expert Consensus Panel”
•    *Co-Author of dubious Study 329 Report: See Emslie note (above).
    On file with CSPI)  http://www.cspinet.org/cgi-bin/integrity.cgi

David Shaffer, MD

Professor of Child Psychiatry, and Professor of Psychiatry and Pediatrics,
Columbia University College of Physicians and Surgeons; Director, Division of Child Psychiatry, New York State Psychiatric Institute
Industry Affiliations:
•    Consultant: Hoffman la Roche, Wyeth (expert trial witness)
•    Consultant: GlaxoSmithKline (on the matter of paroxetine (Paxil) and adolescent suicide)
•    Participated in a consensus panel for child and adolescent bipolar disorder funded by: Abbott, Brystol-Myers Squibb, GlaxoSmithKline, INC Research, Janssen, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, and Solvay.
    Participants did not disclose compensation or affiliations. http://www.liebertpub.com/cap/jcappaper1.pdf
According to the New York Times, "Shaffer…sent a letter at Pfizer’s request to the British drug agency, [saying] he had concluded that there was insufficient data to restrict the use of in adolescents." (NY Times, 12/11/03, A1) http://query.nytimes.com/gst/fullpage.html?res=9C02E4DD173CF932A25751C1A9659C8B63&sec=health&pagewanted=all

Karen Wagner, MD, PhD

Director, Division of Child and Adolescent Psychiatry; Professor and Vice Chair, Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston; ACNP
Industry Affiliations:
•    Consultant: Abbott Laboratories, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories, Glaxo-Smith Kline, Janssen, Novartis, Otskua, Pfizer, UCB Pharma, Wyeth-Ayerst
•    Speaker’s Bureau: Abbott Laboratories, Eli Lilly and Co., Forest Laboratories, Glaxo-Smith Kline, Janssen, Novartis, Pfizer Inc.
•    Advisory Board: Abbott Laboratories, Eli Lilly and Co., Forest Laboratories, Glaxo-Smith Kline, Janssen, Novartis, Otsuka, Pfizer, UCB Pharma, Wyeth-Ayerst
•    Research Support: Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Organon, Pfizer, Wyeth-Ayerst, National Institute of Mental Health
•    Served on Texas Children’s Medication  “Expert Consensus Panel”
•    Co-Author of dubious Study 329 Report: Effacy of paroxetine in the treatment of adolescent major depression (See note at Emslie above)        http://www.cspinet.org/cgi-bin/integrity.cgi

~~~~~~~~

ACNP ACKNOWLEDGMENTS

The ACNP Task Force on SSRIs and Suicide received no fees and the cost of the report was supported solely by the ACNP.
The ACNP also receives a substantial share of its revenue from pharmaceutical industry grants.  
•    The American College of Neuropsychopharmacology gratefully acknowledges the following companies in support of the 44th ACNP Annual Meeting (December 2005):
•    Bristol-Myers Squibb Company; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories; GlaxoSmithKline; Janssen Pharmaceutica Products, L.P. Otsuka Maryland Research; Pfizer Pharmaceuticals; Wyeth Pharmaceuticals http://www.acnp.org/pdffiles/AM2005Program.pdf

*Compiled by Allen Jones, AHRP Board member.